Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Halozyme Therapeutics Says German Court Lifted Injunction on Merck's Keytruda SC

Halozyme Therapeutics Says German Court Lifted Injunction on Merck's Keytruda SC

MT newswireMT newswire2026/11/19 14:13
10:13 AM EST, 11/19/2026 (MT Newswires) -- Halozyme Therapeutics (HALO) said Thursday a German appeals court lifted a preliminary injunction that barred Merck (MRK) from offering or distributing Keytruda SC in Germany. The company will immediately sue Merck for patent infringement in Germany and seek a permanent injunction, Chief Legal Officer Mark Snyder said. In October, a Dutch patent court barred the holder of Merck's European marketing authorization from making, selling or importing the drug in eight European countries, Halozyme said. Halozyme said the MDASE patent dispute will have no effect on licensees' use of its ENHANZE technology or the revenue it earns from those licenses. Shares of the company were down over 3% in Thursday trading. Price: 92.66, Change: -3.14, Percent Change: -3.28
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix

According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.

华尔街见闻•2026/11/21 03:16

"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."

Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.

华尔街见闻•2026/11/21 02:16